Mesoblast (MESO) Enterprise Value (2015 - 2025)
Mesoblast (MESO) posted Enterprise Value of -$130.0 million for Q4 2025, up 19.55% sequentially from -$161.6 million in Q2 2025, and down 241.78% YoY from $91.7 million in Q4 2024.
Mesoblast (MESO) Enterprise Value (2015 - 2025) Analysis & Trends
Mesoblast has reported Enterprise Value for 11 years, with the latest figure at -$130.0 million in Q4 2025.
- Quarterly Enterprise Value fell 241.78% year-over-year to -$130.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$130.0 million (down 241.78% YoY) and the FY2025 annual result came in at -$161.6 million, down 156.59% from the prior year.
- Enterprise Value grew to -$130.0 million in Q4 2025 per MESO's latest filing, from -$161.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$38.0 million in Q4 2024 and troughed at -$161.6 million in Q2 2025.
- A 5-year average of -$92.4 million and a median of -$77.6 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value soared 55.84% in 2022, then slumped 241.78% in 2025.
- Over 5 years, Enterprise Value stood at -$94.8 million in 2021, then rose by 28.71% to -$67.6 million in 2022, then slipped by 14.69% to -$77.6 million in 2023, then surged by 50.96% to -$38.0 million in 2024, then plunged by 241.78% to -$130.0 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$130.0 million, -$161.6 million, and -$38.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | -138.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -129.98 Mn |
| Jun 30, 2025 | -161.55 Mn |
| Dec 31, 2024 | -38.03 Mn |
| Jun 30, 2024 | -62.96 Mn |
| Dec 31, 2023 | -77.55 Mn |
| Jun 30, 2023 | -71.32 Mn |
| Mar 31, 2023 | -48.80 Mn |
| Dec 31, 2022 | -67.62 Mn |
| Sep 30, 2022 | -85.50 Mn |
| Jun 30, 2022 | -60.45 Mn |
| Mar 31, 2022 | -76.76 Mn |
| Dec 31, 2021 | -94.85 Mn |
| Sep 30, 2021 | -115.96 Mn |
| Jun 30, 2021 | -136.88 Mn |
| Mar 31, 2021 | -158.26 Mn |
| Dec 31, 2020 | -77.53 Mn |
| Sep 30, 2020 | -108.12 Mn |
| Jun 30, 2020 | -129.33 Mn |
| Mar 31, 2020 | -60.08 Mn |
| Dec 31, 2019 | -81.35 Mn |